Amy Raymond, PhD, PMP
Executive Director Therapeutic Strategy Lead, Cellular and Genetic Medicines
Dr. Raymond has been a drug discovery and development professional for 20+ years, including progressive roles in rare disease clinical operations and rare disease clinical strategy. Her clinical development experience spans all therapeutic areas and all stages of the clinical development lifecycle, from Natural History studies through in-patient Phase I trials, and Long-Term Follow Up and Post Marketing surveillances.
Ask Dr. Raymond a question
Submit your questions or request a proposal below.
Amy Raymond, PhD, PMP, Executive Director Therapeutic Strategy Lead, Cellular and Genetic Medicines, United States, has been a drug discovery and development professional for 20+ years, including progressive roles in rare disease clinical operations and rare disease clinical strategy. Her clinical development experience spans all therapeutic areas and all stages of the clinical development lifecycle, from Natural History studies through in-patient Phase I trials, and Long-Term Follow Up and Post Marketing surveillances.
In addition to her deep understanding of the unique dynamics of developing novel treatments for rare diseases, Dr. Raymond also leverages her combination of training and experience leading the Cell & Gene Therapy Hub. This experience includes AAV-vectored gene therapies, CAR-T treatments for oncology and non-oncology patient communities, and RNA medicine modalities. Her prior experiences confirm that meeting the needs of all stakeholders - payers, regulators, patients, families, and sites – is a critical success factor for efficient development programs.
Dr. Raymond completed her doctoral training in molecular biology at University of California San Diego and post-doctoral training in molecular biology at Memorial Sloan-Kettering in New York City, New York, USA.
